{"name":"Yuvell","slug":"yuvell","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Letybo®","genericName":"Letybo®","slug":"letybo","indication":"Acute myeloid leukemia (AML) with FLT3-ITD mutation","status":"marketed"}]}],"pipeline":[{"name":"Letybo®","genericName":"Letybo®","slug":"letybo","phase":"marketed","mechanism":"Letybo is a tyrosine kinase inhibitor that targets FLT3 and other kinases to inhibit leukemic cell proliferation.","indications":["Acute myeloid leukemia (AML) with FLT3-ITD mutation"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxPQVllZU1FME12bmhGeHFFY1VZTkNwNkFxa1pGX08yMkRSUk9NWmNMeS0xYnhvTkd5Z1l3Qms5a0EtblAyb1hyek13eVhpYTduLUREME9SVFVuY0xFWG5ZS1Jja1U1Y19rWkRHQ0U5Tjc4X0pYOFJsV0Q2TjJPR0F1Q3pjMjczYktmcnFDSl9NYUNMQ2N3bWJ3SFdsbk55STNReE9VMkRCYWJoMmxadXMwaDAtdEppS25xczQ5TUFPVF9PbkRkSFJmV0l0bXdhVWo2akxhZGtKWTh6aXpHanVBUzE4Z1R2ZEJJbWJsNjVjVk9URmdhRXNZemNWangtbE5TUDd1ZGdTc05wcXdUNXNYRklpWk5wVWE0MlhnOXlxZE9MNlk?oc=5","date":"2025-06-03","type":"trial","source":"PR Newswire","summary":"Nasus Pharma Announces the Publication of Positive Clinical Results from its Phase 2 Study of FMXIN002 (NS002) Intranasal Epinephrine Powder - PR Newswire","headline":"Nasus Pharma Announces the Publication of Positive Clinical Results from its Phase 2 Study of FMXIN002 (NS002) Intranasa","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOYzFrYlpoT1JaOUVPX0FYdjZaR180czd5UTZkSEZ5WHpsa0l6UjJabmJXNW5jVnRoMmlhNGNfdjhCRUZHVVBnT3BBZXhnODQweGpHYlIwZFVJRFl6QTRBM3Bid3VlX2thVmpfSzdiUGFXVFh5QUgybjZQeVp5VTZVLWU4LUZhRnVyeG1qTnN6Vm9YOWNfTWd0VGJ3?oc=5","date":"2022-08-28","type":"deal","source":"Globes - Israel Business News","summary":"Fortissimo buys control of pharmaceutical co CTS - Globes - Israel Business News","headline":"Fortissimo buys control of pharmaceutical co CTS - Globes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFB6RmxDS3c1ZFF3UHJiOEhxUkRwNXc1Ny05MVlUTDdBek1BZ09naWxhSjFSWFppUXZIdDhJTUFjU2RvNlZmbmhjMGpVSDdJem5YMEEwd0ZmRVdEM0hNOTV6NGEwaW9mVXBkSTNRMVVPN081dHFaRTRjcFJVMHQ1d0k?oc=5","date":"2021-08-14","type":"pipeline","source":"PharmaLive","summary":"Q&A with Yuval Cohen, CEO, Corbus Pharmaceuticals - PharmaLive","headline":"Q&A with Yuval Cohen, CEO, Corbus Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE5vaGZQVmxrb29rU3NTVGQ0SDRqSTh0WFRMZnpSU0tBYUdoSUtodXdMWDNSRkhHNlhWMXFudENlRkxNOFoyN1QxOWdnTkJuWW9SRzh4Szg0cmo2RWxxUk81Y2JLNm1jbmZMNk5QYUdRUzlWTGtNYzZKSk9lUzg?oc=5","date":"2015-05-28","type":"pipeline","source":"BioSpace","summary":"Day in the Life of a CEO—Yuval Cohen, Corbus - BioSpace","headline":"Day in the Life of a CEO—Yuval Cohen, Corbus","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}